As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials
Executive Summary
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.
You may also be interested in...
Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.
Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent
With Janssen’s Stelara set to lose its exclusivity in September 2023, the originator is looking to ward off potential biosimilar competition from Amgen by suing the firm for patent infringement in a US district court.
Amgen Mvasi, Kanjinti Sales Decline As Biosimilars Industry Faces New Policy Challenges
ASP metric used in Medicare, and often in commercial insurance, for reimbursement of physician-administered drugs is an important factor in the sales arc for biosimilars. Price negotiations under IRA could bring their own margin-squeezing pain to pharmacy-benefit biosimilars.